Rating Change
Wells Fargo analysts reiterated a Equal-Weight rating on ResMed Inc. (NYSE:RMD) on July 08, 2026.
reiterateNYSE:RMD
Wells Fargo Reiterates Equal-Weight Rating on ResMed Inc. (RMD)
Rating Change Wells Fargo analysts reiterated a Equal-Weight rating on ResMed Inc. (NYSE:RMD) on July 08, 2026. Market Context ResMed Inc.
Market Context
ResMed Inc. operates in the Healthcare sector. The stock currently trades at $205.84 with a market capitalization of $37.0B. The stock has declined 10.4% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ResMed Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ResMed Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | RBC Capital | Outperform | N/A |
| Jul 08, 2026 | Wells Fargo | Equal-Weight | N/A |
| Jun 22, 2026 | Keybanc | Overweight | N/A |
| Jun 17, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Jun 15, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RMD Stock Page
Frequently Asked Questions
What does a Equal-Weight rating mean for RMD?
A Equal-Weight rating from Wells Fargo reflects the analyst's outlook on ResMed Inc. (NYSE:RMD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RMD forecast page.
